Abstract
Although cohort studies which are based on intention-to-treat (ITT) approach offer a simple design with data which are simpler to analyse and results easier to interpret, such studies also intrinsically assume that any time-varying treatment effect that exits can be adequately estimated by a fixed-effect component. However, such an assumption may not reflect real-life drug use. Reflection of real-life clinical practice is a major strength of epidemiologic safety studies. The failure to properly reflect reality may result in effect under-estimation leading to false and irreproducible conclusions due to exposure misclassification. In effect, the use of nested case-control design is a concession that ITT in cohort design may not be adequate. But the nested design also has its own sources of bias, including confounding by indication. We present an overview of the counter-matched version of the nested case-control, case-crossover, case-in-time, case series and case-cohort designs as alternatives in prospective post-authorization safety studies.
Keywords: Cohort study, selection bias, case-control design, counter-matching
Current Drug Safety
Title: How Real is Intention-To-Treat (ITT) Analysis in Non-Interventional Post Authorization Safety Studies? We Can Do Better
Volume: 4 Issue: 2
Author(s): Victor A. Kiri and Gilbert MacKenzie
Affiliation:
Keywords: Cohort study, selection bias, case-control design, counter-matching
Abstract: Although cohort studies which are based on intention-to-treat (ITT) approach offer a simple design with data which are simpler to analyse and results easier to interpret, such studies also intrinsically assume that any time-varying treatment effect that exits can be adequately estimated by a fixed-effect component. However, such an assumption may not reflect real-life drug use. Reflection of real-life clinical practice is a major strength of epidemiologic safety studies. The failure to properly reflect reality may result in effect under-estimation leading to false and irreproducible conclusions due to exposure misclassification. In effect, the use of nested case-control design is a concession that ITT in cohort design may not be adequate. But the nested design also has its own sources of bias, including confounding by indication. We present an overview of the counter-matched version of the nested case-control, case-crossover, case-in-time, case series and case-cohort designs as alternatives in prospective post-authorization safety studies.
Export Options
About this article
Cite this article as:
Kiri A. Victor and MacKenzie Gilbert, How Real is Intention-To-Treat (ITT) Analysis in Non-Interventional Post Authorization Safety Studies? We Can Do Better, Current Drug Safety 2009; 4 (2) . https://dx.doi.org/10.2174/157488609788173008
DOI https://dx.doi.org/10.2174/157488609788173008 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment
Current Pharmaceutical Design Blood-Brain Barrier Transport of Short Proline-Rich Antimicrobial Peptides
Protein & Peptide Letters Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Current Molecular Medicine Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Clinical Presentation of Autoinflammatory Syndromes in Childhood
Current Rheumatology Reviews Magnetic Resonance Imaging of Short T2 Relaxation Components in Tissue Using Ultrashort Echo Time (UTE) Pulse Sequences
Current Medical Imaging Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Childhood Systemic Lupus Erythematosus: New and Old Treatments
Current Pediatric Reviews Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Current Drug Targets Recent Advances in Peptide Nucleic Acids as Antibacterial Agents
Current Medicinal Chemistry